Industries > Pharma > Biologics Market Trends and Forecasts 2018-2028

Biologics Market Trends and Forecasts 2018-2028

Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Factors, Interferons, Enzyme Replacement, Stem Cell Therapies, Tissue Engineered Products, Gene Therapies

PUBLISHED: 14 November 2018
PAGES: 303
PRODUCT CODE: PHA0341

Clear
WOOCS 2.2.1

The global biologics market is estimated to reach $250bn in 2023. The market is expected to grow at a CAGR of 4.8% from 2018 to 2023. In 2017, the monoclonal antibodies submarket held 36.3% share of the global biologics market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 303-page report you will receive 166 charts– all unavailable elsewhere.

The 303-page report provides clear detailed insight into the global biologics market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Biologics Market outlook from 2018-2028

Global Biologics Submarkets analysis and forecast from 2018-2028:
Protein therapeutics, with sub-forecasting for insulin, other recombinant hormones, plasma and recombinant coagulating factors, interferons, enzyme replacement and other agents
Monoclonal antibodies (mAbs)
Fusion proteins
Regenerative medicine, with sub-forecasting for stem cell treatment, tissue engineering and gene therapy
Vaccines

• Analysis and forecast from 2018-2028 for selected leading biologics in the market:
• Lantus
• NovoLog/NovoRapid
• Humalog
• Avonex
• Rebif
• Humira
• Remicade
• Tysabri
• Herceptin
• Kadcyla
• Perjeta
• Enbrel
• Eylea
• OsteoCel Plus
• Trinity Evolution and Trinity Elite
• Apligraf
• Dermagraft
• IMLYGIC

Biologics Market Trends and Forecasts 2018-2028

• This report provides individual revenue forecasts from 2018-2028 for these national markets:
• The US
• Japan
• Germany
• France
• UK
• Italy
• Spain
• China
• India
• Russia
• Brazil

• Our study discusses the selected leading companies that are the major players in the biologics market:
• AbbVie
• Amgen
• AstraZeneca
• Bayer
• Eli Lilly
• GlaxoSmithKline (GSK)
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis
• Pfizer
• Roche
• Sanofi S.A.

• This report discusses factors that drive and restrain this market. As well as opportunities and trends in this market.

• This report discusses the SWOT and STEP Analysis of the biologics market.

Visiongain’s study is intended for anyone requiring commercial analyses for the biologics market. You find data, trends and predictions.

Buy our report today Biologics Market Trends and Forecasts 2018-2028: Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Factors, Interferons, Enzyme Replacement, Stem Cell Therapies, Tissue Engineered Products, Gene Therapies.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Biologics Market Trends and Forecasts 2018-2028


Download sample pages

Complete the form below to download your free sample pages for Biologics Market Trends and Forecasts 2018-2028


Latest Pharma news

Visiongain Publishes Pharma Contract Manufacturing Market Report 2020-2030

Fierce competition, stringent regulations, diminishing research and development, shrinking margins, strong price pressures and patent cliffs encompass today’s drug industry.

10 August 2020

READ

Visiongain Publishes Biologics Market Report 2020-2030

Biosimilars will be changing the biologics market in the long term. But whether it does it for the better or the worse will depend on how the producers of biologics respond to their market presence.

06 August 2020

READ

Visiongain Publishes Biochips Market Report 2020-2030

Conceptually, it is clear for all stakeholders in the health care segment as well in the biotechnological sector the benefits are evident since it will improve the speed and accuracy of diagnostics or analysis.

05 August 2020

READ

Visiongain Publishes Cell and Gene Supply Chain Services and Solutions Market Report 2020-2030

With the threat of growing number of patients due to the COVID-19 infections, the supply chain trends are looking at a shift with no contact and social distancing policies.

03 August 2020

READ

Categories

Category